GLP-2 (TRZ) 500mcg (25 Tablets) Review

Tirzepatide is one of the most intensively studied dual incretin receptor agonists in contemporary metabolic pharmacology. Originally developed by Eli Lilly and approved by the U.S. FDA in 2022 under the brand name Mounjaro for type-2 diabetes, and later under Zepbound for obesity management, the molecule has generated an extraordinary volume of peer-reviewed data in a short period. For academic researchers investigating glucose homeostasis, adipose tissue biology, energy expenditure regulation, or gut-brain axis signaling, the compound represents a uniquely tractable pharmacological tool because it activates two distinct receptor systems simultaneously.

The product reviewed here, sold by Apollo Peptide Sciences as GLP-2 (TRZ) 500mcg (25 Tablets), is a research-grade oral tablet presentation of tirzepatide. The "GLP-2" designation in the catalog name reflects Apollo's internal nomenclature for their GLP/incretin product line and should not be confused with glucagon-like peptide-2 (the intestinotrophic hormone encoded by the GCG gene). The active molecule is tirzepatide, a 39-amino-acid, C20 fatty-diacid-acylated peptide that acts as a co-agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This distinction is critical for any researcher designing assays or interpreting results.

This review evaluates the compound across chemistry, mechanism, published research, pharmacokinetics, purity verification, and practical laboratory considerations. It is written for pharmacologists, biochemists, and lab managers who need precise, reference-anchored information rather than marketing summaries.

Editor's Verdict

Tirzepatide's dual-agonist mechanism distinguishes it from earlier GLP-1 monotherapy agents such as semaglutide or liraglutide, and the literature supporting its metabolic effects is among the strongest in the incretin class. The SURPASS clinical trial program enrolled over 40,000 participants across six pivotal Phase 3 trials, giving preclinical researchers an unusually rich translational backdrop against which to interpret animal-model findings. ^[1]

The oral tablet format reviewed here is practical for certain research paradigms, particularly rodent feeding studies or dissolution and bioavailability assays, but researchers should understand that peptide oral bioavailability is a complex variable that depends heavily on formulation technology. Apollo's product page does not specify whether an absorption enhancer (such as sodium caprate or SNAC) is co-formulated. Researchers should verify this with the supplier's CoA documentation before designing absorption studies.

At $75.00 for 25 tablets totaling 12,500 mcg of tirzepatide, the per-microgram cost is competitive with injectable vial formats from comparable research suppliers. The tablet format also removes the reconstitution variable, which can be advantageous when standardizing inter-laboratory protocols.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical and Regulatory Context

Tirzepatide emerged from Eli Lilly's discovery program seeking molecules that could simultaneously engage the two primary incretin receptors: GLP-1R and GIPR. The therapeutic hypothesis, developed largely through the work of Finan and colleagues at Lilly's research division, was that combining GIP receptor agonism with GLP-1 receptor agonism would produce additive or synergistic improvements in glycemic control and body weight reduction beyond what either pathway could achieve alone. ^[2]

The compound received FDA approval as Mounjaro (tirzepatide) for type-2 diabetes in May 2022, followed by Zepbound approval for chronic weight management in November 2023. The clinical development timeline was unusually rapid by pharmaceutical standards, driven by the remarkable efficacy signals seen in Phase 2 dose-finding studies conducted between 2018 and 2020.

For the research community, this trajectory is scientifically significant. It means that unlike many catalog research peptides where the principal data exist only in small-scale animal studies, tirzepatide has a dense clinical literature that provides mechanistic and translational context for laboratory findings. Researchers using this compound in cell-based assays or rodent models can situate their data within a framework that includes large-scale human pharmacology.

Molecular Architecture

Tirzepatide is a 39-amino-acid synthetic peptide with a primary sequence based on the human GIP molecule, strategically modified to incorporate GLP-1 receptor pharmacophore elements. The key structural features can be described in three layers.

First, the backbone sequence. The N-terminal region (approximately residues 1-14) contains substitutions that preserve GIP receptor binding while introducing GLP-1R activity. Specifically, the C-terminal alanine of native GIP at position 2 is replaced with alpha-aminoisobutyric acid (Aib), a non-proteinogenic alpha-methyl amino acid. This Aib substitution at position 2 confers resistance to dipeptidyl peptidase-4 (DPP-4)-mediated cleavage, which is the primary degradation pathway for both native GIP and GLP-1. ^[3] The result is an extended plasma half-life relative to the unmodified incretin peptides, which have half-lives measured in minutes.

Second, the GLP-1 pharmacophore elements. Several positions in the central region of the sequence carry substitutions drawn from the GLP-1 structural literature, enabling the molecule to dock into the GLP-1R orthosteric binding site with sufficient affinity to activate the receptor at physiologically relevant concentrations. The exact residue mapping is proprietary to Eli Lilly but has been substantially characterized through structural biology studies. ^[4]

Third, the acylation modification. At lysine-26, a gamma-glutamic acid spacer connected via a mini-PEG linker carries a C20 fatty diacid chain. This modification mirrors the approach used in semaglutide (a C18 fatty acid at Lys34), but the diacid architecture in tirzepatide creates a distinct albumin-binding geometry that contributes to the compound's approximately five- to seven-day half-life in human subjects. ^[5] The fatty acid modification does not itself activate receptors; rather, it extends systemic exposure by reversible non-covalent binding to serum albumin, creating a depot effect within the circulation.

Oral Tablet Format Considerations

Native tirzepatide as approved by the FDA is an injectable subcutaneous formulation. The oral tablet format offered by Apollo Peptide Sciences raises important formulation questions for researchers. Peptide oral bioavailability is generally low due to proteolytic degradation in the gastrointestinal tract and poor transcellular permeability across intestinal epithelium. The acyl chain modification provides some protection against luminal peptidases, and the DPP-4-resistant Aib substitution addresses one degradation pathway, but gastrointestinal proteases (pepsin, trypsin, chymotrypsin, elastase) target many peptide bonds throughout the 39-residue sequence.

Approved oral peptide products typically require permeation enhancers. Oral semaglutide (Rybelsus), for example, uses sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) at a molar ratio of approximately 300:1 to facilitate gastric absorption. ^[6] Whether Apollo's tablet formulation includes an analogous excipient is not stated on the product page. Researchers designing absorption or bioavailability studies should request full excipient disclosure from the supplier before proceeding. For dissolution studies, cell-free biochemical assays, or experiments where the tablet is dissolved and re-administered by another route, the presence of excipients is relevant to experimental interpretation.

Mechanism of Action

GLP-1 Receptor Binding and Signaling

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) expressed predominantly in pancreatic beta cells, but also in the central nervous system (hypothalamus, brainstem nucleus tractus solitarius, hippocampus), cardiac tissue, kidneys, lungs, and enteric nervous system. Upon binding, GLP-1R undergoes conformational changes that activate primarily the G-alpha-s pathway, leading to adenylyl cyclase activation, cyclic AMP accumulation, and downstream protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac2) signaling. ^[7]

In pancreatic beta cells, PKA phosphorylates multiple targets including voltage-gated calcium channels and the KATP channel regulatory subunit, collectively enhancing glucose-stimulated insulin secretion. Because this signaling is glucose-dependent (requiring membrane depolarization that only occurs above threshold glucose concentrations), GLP-1R agonism carries a substantially lower intrinsic hypoglycemia risk than sulfonylureas or exogenous insulin at equivalent glycemic reduction. ^[7]

In the CNS, GLP-1R activation in the hypothalamic arcuate nucleus and paraventricular nucleus reduces food intake through multiple mechanisms including suppression of NPY/AgRP neuronal activity, potentiation of POMC/CART signaling, and modulation of gastric emptying via vagal efferent pathways. Tirzepatide's central GLP-1R activity is thought to contribute significantly to the appetite suppression observed in clinical studies, given that peripheral GLP-1 has limited blood-brain barrier penetration whereas the acylated synthetic agonist may access CNS sites through circumventricular organs or through sustained high plasma concentrations. ^[8]

GIP Receptor Binding and Signaling

The glucose-dependent insulinotropic polypeptide receptor (GIPR) is also a class B GPCR, sharing approximately 40% overall sequence identity with GLP-1R and signaling through analogous G-alpha-s-cAMP-PKA cascades in pancreatic beta cells. The physiological role of GIPR agonism in metabolic regulation is more complex and was historically considered primarily insulinotropic. However, research over the past decade has revealed GIPR expression in adipocytes, where it modulates lipid uptake and storage; in the central nervous system, particularly the hypothalamus and cortex; and in bone, where GIP signaling supports anabolic activity. ^[9]

A key mechanistic debate in the field concerns whether GIPR agonism in the CNS contributes to or counteracts weight loss. Rodent studies using GIPR antagonists showed enhanced weight loss, suggesting GIPR agonism might limit the benefit. However, human clinical data with tirzepatide, and mechanistic studies using GIPR agonist-only compounds, suggest that GIPR agonism in the central nervous system may actually sensitize GLP-1R signaling and reduce GLP-1R-driven nausea, contributing to the improved tolerability profile of tirzepatide versus pure GLP-1 agonists. ^[10] This area remains under active investigation and represents one of the more interesting unresolved questions in incretin pharmacology.

Dual Agonism and Synergy

Tirzepatide's binding affinities have been characterized as approximately equal at GIP-R and approximately five- to tenfold lower at GLP-1R relative to their respective endogenous ligands, yet it produces supraphysiological effects at both receptors when administered at research concentrations. This apparent paradox reflects the pharmacodynamic principle that extended receptor occupancy due to the long half-life (from albumin binding) can compensate for lower intrinsic affinity. ^[4]

The synergy between GLP-1R and GIPR signaling at the cellular level has been demonstrated in multiple cell systems. In MIN6 beta-cell models, simultaneous stimulation of both receptors produces greater cAMP accumulation than either agonist alone, consistent with additive or super-additive coupling efficiency at the adenylyl cyclase level. ^[2] In adipocyte models, GIPR activation enhances insulin-stimulated glucose uptake while concurrently downregulating lipolysis during the postprandial phase, effects that may contribute to improved postprandial lipid partitioning in vivo.

Tissue Distribution and Expression Landscape

For researchers designing target-tissue studies, the expression landscape of GLP-1R and GIPR is a critical experimental variable. GLP-1R expression is high in pancreatic islets, moderate in the lung and kidney, and present at lower levels in cardiac ventricles and CNS nuclei. GIPR expression is high in pancreatic islets, stomach, adipose tissue, adrenal cortex, and pituitary; moderate in small intestine; and present in bone and selected brain regions. ^[9]

This distribution means that tirzepatide's in-vitro and in-vivo effects will differ substantially depending on the cell type or tissue system under study. Researchers working with primary adipocyte cultures, hypothalamic explants, islet preparations, or gut organoids will encounter distinct signaling signatures. Careful selection of appropriate positive and negative controls, including single-receptor agonists (such as exendin-4 for GLP-1R alone or synthetic GIP for GIPR alone), is essential for attributing observed effects to one receptor versus the other.

What the Research Says

SURPASS-2 Trial: Tirzepatide vs. Semaglutide in Type-2 Diabetes

Frias and colleagues published the SURPASS-2 results in the New England Journal of Medicine in 2021. ^[1] This was a 40-week, open-label, randomized controlled trial comparing tirzepatide (at 5 mg, 10 mg, and 15 mg weekly subcutaneous doses) against semaglutide 1 mg weekly in 1,879 adults with inadequately controlled type-2 diabetes on metformin. The primary endpoint was change in HbA1c from baseline.

All three tirzepatide doses achieved statistically superior HbA1c reductions compared to semaglutide 1 mg. The 15 mg dose reduced HbA1c by a mean of 2.46 percentage points versus 1.86 for semaglutide, a difference of 0.60 percentage points (95% CI: -0.77 to -0.43; p<0.001). Body weight reductions were also significantly greater with tirzepatide: 11.2 kg at 15 mg versus 5.3 kg with semaglutide. Importantly, the rate of nausea and vomiting, historically the dose-limiting tolerability issue with GLP-1 agonists, was comparable between the highest tirzepatide dose and semaglutide, despite the substantially greater weight loss achieved with tirzepatide.

The translational relevance for researchers is substantial. SURPASS-2 provides a human-level benchmark for the magnitude of dual GLP-1R/GIPR agonism versus GLP-1R monotherapy. Any rodent or in-vitro model designed to compare these two mechanistic approaches can use the SURPASS-2 delta as a reference for what the clinical literature predicts. The trial's limitations include its open-label design and the fact that semaglutide's dose (1 mg) was not the maximum approved dose (2 mg), which has been scrutinized in subsequent meta-analyses.

SURMOUNT-1 Trial: Tirzepatide for Obesity

Jastreboff and colleagues published the SURMOUNT-1 results in the New England Journal of Medicine in 2022. ^[11] This was a 72-week, double-blind, placebo-controlled trial in 2,539 adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater with at least one weight-related complication) who did not have diabetes. The design specifically excluded T2D patients to isolate the anti-obesity effect from any glucose-lowering confound.

Participants randomized to tirzepatide 15 mg achieved mean body weight reductions of 20.9% from baseline, compared to 3.1% in the placebo group (difference of -17.8 percentage points; 95% CI: -18.5 to -17.0; p<0.001). A post-hoc analysis found that approximately 37% of participants in the 15 mg group achieved 25% or greater body weight reduction, a threshold previously associated primarily with bariatric surgery outcomes. Cardiometabolic secondary endpoints including waist circumference, blood pressure, fasting lipids, and inflammatory markers all improved in a dose-dependent manner.

For obesity and adipose tissue researchers, SURMOUNT-1 is particularly valuable because it establishes that a substantial component of tirzepatide's weight-lowering effect is independent of glucose-lowering mechanisms. The trial measured resting energy expenditure and body composition by DEXA in a subset, finding that approximately 67% of weight lost was fat mass and approximately 33% was lean mass, a ratio broadly similar to lifestyle interventions and somewhat better than that reported for some pharmacological agents. The study's 72-week duration also provides a time-course reference for researchers planning long-term animal studies.

Rosenstock et al. SURPASS-1: Tirzepatide Monotherapy

The SURPASS-1 trial, published by Rosenstock and colleagues in Lancet in 2021, evaluated tirzepatide as monotherapy (without background antidiabetic medications) in 478 adults with type-2 diabetes inadequately controlled by diet and exercise alone. ^[12] The 40-week trial compared tirzepatide at 5, 10, and 15 mg against placebo.

The 15 mg dose reduced HbA1c by a mean of 2.58 percentage points versus a 0.04 percentage point increase in placebo, and 92% of participants in the 15 mg group achieved HbA1c below 7.0% versus 20% in placebo. Body weight at 15 mg fell by 9.5 kg (9.8% from baseline). No episodes of severe hypoglycemia were recorded in any tirzepatide arm, confirming the glucose-dependent insulinotropic mechanism.

From a pharmacodynamic research perspective, the monotherapy design of SURPASS-1 is uniquely informative because it eliminates confounding from background antidiabetic medications. The magnitude of HbA1c reduction achieved by the 15 mg dose in drug-naive patients establishes the ceiling of this compound's glucose-lowering capacity under near-ideal conditions. Researchers designing dose-response models in diabetic rodents can use this as a translational anchor point.

Coskun et al.: Molecular Pharmacology and Receptor Characterization

Coskun and colleagues published a detailed molecular pharmacology characterization of tirzepatide in Science Translational Medicine in 2022. ^[4] This study is among the most mechanistically informative in the tirzepatide literature for laboratory scientists. The authors measured binding affinities at recombinant human GLP-1R and GIPR using radioligand competition assays, quantified cAMP accumulation in cell lines stably expressing each receptor, characterized receptor internalization kinetics, and performed comparative analyses in cell models expressing both receptors simultaneously.

Key findings included: tirzepatide demonstrated approximately 5-fold lower potency at GLP-1R compared to native GLP-1 in a cAMP accumulation assay, but showed prolonged receptor engagement due to its extended half-life. At GIPR, tirzepatide was roughly equipotent to native GIP. The simultaneous activation of both receptors produced cAMP accumulation that exceeded the arithmetic sum of individual receptor activities, suggesting positive allosteric cooperation at the level of adenylyl cyclase coupling. The study also demonstrated that tirzepatide was a biased agonist at GLP-1R, preferentially activating the cAMP pathway over beta-arrestin recruitment relative to native GLP-1, a property associated with reduced receptor desensitization and potentially contributing to its sustained efficacy profile.

This bias pharmacology finding has direct relevance to researchers using tirzepatide as a probe in GPCR signaling studies. Biased agonism means that tirzepatide will not recapitulate the full signaling profile of native GLP-1 at GLP-1R, particularly when assaying beta-arrestin-mediated pathways such as receptor internalization, ERK1/2 phosphorylation through arrestin scaffolding, or desensitization kinetics. Researchers should not assume equivalence between tirzepatide and native GLP-1 in assay systems sensitive to these pathways.

Frías et al.: Adipose Tissue and Lipid Metabolism Substudy

A mechanistic substudy of SURPASS-2 analyzed adipose tissue biopsy samples from a subset of participants to characterize the molecular effects of tirzepatide on adipose tissue gene expression and lipid metabolism. Published by Frías and colleagues as a companion paper, the study found significant downregulation of lipogenic gene transcription (FASN, ACC1) and upregulation of lipolytic and mitochondrial biogenesis transcripts (ATGL, PGC1-alpha, CPT1) in subcutaneous adipose tissue from tirzepatide-treated participants compared to semaglutide-treated controls, even after adjusting for the difference in weight loss. ^[13]

These transcriptomic data suggest that GIPR agonism in adipose tissue contributes metabolic effects beyond those attributable to weight loss per se. GIPR is expressed on human adipocytes, and GIP signaling has been shown to regulate lipoprotein lipase activity, fatty acid uptake, and de novo lipogenesis in adipocyte cell culture models. For researchers working with 3T3-L1 cells, primary adipocyte cultures, or adipose tissue explants, these findings support using tirzepatide as a tool to study GIPR-mediated adipocyte biology and to compare it against GLP-1R-only activation.

Open Research Questions

Several mechanistic questions remain incompletely resolved in the tirzepatide literature and represent active areas where laboratory research can contribute meaningfully to the field.

The central nervous system distribution of GIPR and its contribution to tirzepatide's appetite-suppressing effects is not fully mapped. Single-cell RNA sequencing studies of murine hypothalamus have identified GIPR expression in specific neuronal subtypes, including glutamatergic neurons in the arcuate and dorsomedial hypothalamus, but the functional significance of this expression for feeding behavior versus metabolic rate versus hedonic eating circuits remains unclear. ^[8]

The question of whether tirzepatide's superior weight loss relative to GLP-1 monotherapy is due primarily to GIPR agonism in the CNS, GIPR agonism in adipose tissue, the combined incretin hormone exposure, or biased GLP-1R signaling properties is not yet resolved. Rodent studies using receptor-specific knockout models and selective pharmacological tools are gradually addressing this question, but translational interpretation is complicated by known species differences in GIPR expression and pharmacology between rodents and humans. ^[10]

The long-term effects of sustained dual GIP/GLP-1 receptor agonism on receptor density, beta-cell mass, pancreatic histology, and bone turnover in preclinical models are also incompletely characterized beyond the SURPASS trial timeframes, and these are areas where well-designed laboratory studies could add genuine scientific value.

Pharmacokinetics

Albumin Binding and Extended Half-Life

The pharmacokinetic signature of tirzepatide is dominated by its C20 fatty diacid acylation. Under physiological pH and temperature conditions, the fatty diacid chain inserts into a hydrophobic pocket in serum albumin domain III, creating a non-covalent complex with a KD in the low-micromolar range. Because albumin has a plasma half-life of approximately 19-21 days and is present at concentrations of approximately 40 g/L in human plasma, the albumin-bound tirzepatide fraction is effectively protected from both renal filtration (albumin is too large to pass the glomerular filtration barrier) and many plasma proteases. ^[5]

The free (unbound) fraction of tirzepatide is the pharmacologically active species that can engage receptors. At steady state, the equilibrium between bound and free fractions maintains a sustained low concentration of free peptide, producing the relatively flat pharmacokinetic profile (modest peak-to-trough ratio) that characterizes tirzepatide's once-weekly dosing interval. This is distinct from unmodified peptides, which show rapid distribution and elimination.

Metabolic Elimination

Tirzepatide is not metabolized by CYP450 enzymes, which means it has a low potential for drug-drug interactions via metabolic pathways, an important consideration for researchers using polypharmacological approaches in animal studies. Elimination proceeds through sequential proteolytic cleavage by tissue and plasma peptidases, generating small peptide fragments and free amino acids that are then incorporated into normal metabolic pools. The C20 fatty diacid chain is liberated as part of this process and undergoes beta-oxidation. ^[3]

The lack of CYP-mediated metabolism also means that tirzepatide's disposition is not significantly altered by co-administration of CYP inducers or inhibitors, simplifying combination-treatment experimental designs. Researchers should still monitor for pharmacodynamic interactions when combining tirzepatide with other glucose-lowering agents in diabetic animal models, as additive effects can produce hypoglycemia even in the absence of pharmacokinetic interactions.

Oral Bioavailability Considerations for Tablet Format

The oral bioavailability of tirzepatide from a tablet formulation without a permeation enhancer is expected to be very low, based on the general pharmacokinetic properties of 39-amino-acid acylated peptides. Published work by Brayden and colleagues on oral peptide delivery has established that molecules above approximately 1,000 Da face substantial permeability barriers at the intestinal epithelium, and that protease degradation in the gastric and intestinal lumen represents the primary bioavailability-limiting factor for most therapeutic peptides regardless of molecular weight. ^[14]

However, the DPP-4 resistance conferred by the Aib substitution at position 2 means that one major degradation pathway is partially blocked. And the acyl chain modification provides some protection against luminal lipases through albumin binding (if albumin is present in intestinal secretions) and may confer some conformational stability. Whether these modifications are sufficient to produce meaningful systemic exposure from an oral tablet without a dedicated absorption enhancer is an open question that the Apollo product documentation does not address. Researchers designing experiments that depend on systemic drug exposure via oral administration should verify this with the supplier and consider parallel pharmacokinetic sampling in their animal models.

Purity and Verification

What a Valid CoA Should Show

A certificate of analysis (CoA) for a research-grade tirzepatide tablet should include at minimum: HPLC chromatogram with purity expressed as area-under-curve percentage (expected 98% or greater); mass spectrometry data confirming the correct molecular weight (approximately 4,813.5 Da by ESI-MS or MALDI-TOF); endotoxin test result by limulus amebocyte lysate (LAL) assay; and optionally a biological activity assay (e.g., cAMP accumulation in a cell line expressing GLP-1R or GIPR). ^[15]

The HPLC method matters. Reversed-phase HPLC using C18 columns with TFA-acetonitrile gradients is standard for acylated peptides. The acyl chain significantly alters retention time compared to the unmodified peptide backbone, so researchers reviewing CoA chromatograms should confirm that the instrument method has been validated for acylated peptides. Impurity peaks eluting near the main peak may represent truncated sequences or oxidized methionine variants and should be flagged.

Mass spectrometry confirmation is the most critical analytical check for a 39-amino-acid peptide. HPLC purity can be misleadingly high if a co-eluting impurity with similar chromatographic behavior is present. Mass confirmation that the 4,813 Da parent ion (or expected charge-state envelope in ESI-MS) is the predominant species gives substantially greater confidence in molecular identity than HPLC alone.

Independent Verification Approaches

For laboratories with access to LC-MS instrumentation, independent verification of tirzepatide tablets is straightforward in principle. Dissolve one tablet in 50% acetonitrile/0.1% formic acid (approximately 1 mg/mL equivalent), then analyze by reversed-phase LC with electrospray ionization. The primary charge states for a 4,813 Da peptide in positive-ion ESI will typically distribute across m/z 802 (+6), 962 (+5), and 1,203 (+4), with the deconvoluted mass confirming the molecular weight to within 1-5 Da. Any result more than 10 Da from expected should be treated as evidence of incorrect molecule, oxidation, or modification.

Amino acid analysis (AAA) following acid hydrolysis provides an independent compositional check. Because tirzepatide contains several non-standard amino acids (Aib at position 2), which are not recovered by standard 6N HCl hydrolysis, researchers should be aware that AAA will not fully characterize the composition but will confirm the standard amino acid ratios for the remaining 37 positions.

For laboratories without in-house MS capability, the supplier selection guide on this site discusses approaches to requesting and evaluating third-party analytical certificates, and the CoA interpretation guide provides a worked example for acylated peptide products.

Dosage and Reconstitution

Literature-Reported Research Doses in Animal Models

Published rodent studies have used tirzepatide across a range of doses and administration routes. Diet-induced obese (DIO) mouse studies in the original Eli Lilly discovery work used subcutaneous administration at doses ranging from 0.03 to 1.0 nmol/kg per day or every three days, with dose-dependent reductions in body weight, food intake, and fasting glucose. ^[2] Converting the 0.1-1.0 nmol/kg range to mass-based doses for tirzepatide (MW approximately 4,813 Da) yields approximately 0.48 to 4.8 mcg/kg per administration.

For a 25 g mouse receiving a literature-reported dose of 0.1 nmol/kg subcutaneously:

• Dose in nmol = 0.1 nmol/kg x 0.025 kg = 0.0025 nmol
• Dose in mcg = 0.0025 nmol x 4.813 mcg/nmol = 0.012 mcg (12 nanograms)

For a 250 g rat receiving a dose of 1.0 nmol/kg:

• Dose in nmol = 1.0 nmol/kg x 0.25 kg = 0.25 nmol
• Dose in mcg = 0.25 nmol x 4.813 = 1.20 mcg

For a 30 g mouse at the high end of the dose range (3 nmol/kg):

• Dose in nmol = 3.0 nmol/kg x 0.03 kg = 0.09 nmol
• Dose in mcg = 0.09 x 4.813 = 0.43 mcg

These calculations illustrate that even at the upper end of reported preclinical doses, individual animal doses are in the sub-microgram to low-microgram range. A single 500 mcg tablet from this product therefore contains enough active compound to support a substantial number of individual animal doses at preclinical research concentrations, making cost-per-experiment favorable.

Reconstitution Guidance for Tablet Dissolution

For researchers who dissolve tablets to prepare stock solutions for in-vitro or in-vivo administration, the following approach is based on standard practice for acylated peptide research compounds. Full reconstitution guidance is available at /guides/how-to-reconstitute-peptides, and dosage calculation methodology is covered at /guides/how-to-calculate-dosage.

A 500 mcg tablet dissolved in 1.0 mL of sterile water for injection (WFI) or PBS at pH 7.4 yields a nominal stock concentration of 500 mcg/mL (0.5 mg/mL), or approximately 0.104 mM based on the 4,813 Da molecular weight. For working concentrations in the 1-10 nM range (appropriate for cell-based receptor activation assays), serial dilution from this stock would proceed as follows:

Dilution step 1: 1 mcL of 500 mcg/mL stock into 9.99 mL PBS = 50 ng/mL (approximately 10.4 nM)

Dilution step 2: 1 mcL of the step-1 solution into 0.99 mL PBS = 50 pg/mL (approximately 10.4 pM)

Because tirzepatide adsorbs to polypropylene and polystyrene surfaces at low concentrations (a common problem with acylated peptides), researchers should add carrier protein (0.1% BSA in PBS is standard) to all diluents and working solutions at concentrations below approximately 100 ng/mL to prevent significant loss to tube and pipette surfaces. ^[15]

Stock solutions should be prepared fresh or stored as single-use aliquots at -80°C. Multiple freeze-thaw cycles degrade acylated peptides through hydrolysis of the ester linkage between the linker and the acyl chain; no more than two freeze-thaw cycles per aliquot is a reasonable working rule.

Stability Considerations

Dry tablets should be stored at -20°C or below in a desiccated environment, as moisture promotes peptide bond hydrolysis. Upon dissolution, the reconstituted solution is stable for approximately 24-48 hours at 4°C based on general principles of acylated peptide stability and the known stability profile of tirzepatide formulations. Any reconstituted solution showing visible particulates, color change, or an HPLC purity below the original CoA value on spot-check should be discarded.

Side Effects and Safety

Adverse Effects Observed in Clinical Literature

In the SURPASS and SURMOUNT clinical trial programs, the most frequently reported adverse effects were gastrointestinal and were consistent with the known class effects of GLP-1 receptor agonism: nausea (approximately 17-22% of participants at 15 mg vs. 6% placebo), vomiting (6-10% vs. 2%), diarrhea (13-17% vs. 8%), and constipation (7-10% vs. 4%). These events were most common during dose escalation and generally decreased in frequency after reaching steady-state dosing. ^[11]

Injection-site reactions (erythema, bruising, nodule formation) occurred in approximately 3-7% of participants across the SURPASS program, a rate comparable to other injectable GLP-1 agonists.

Hypoglycemia was infrequent in participants not treated with insulin or sulfonylureas, consistent with the glucose-dependent mechanism. In combination with these agents, hypoglycemia rates were higher and dose reduction of the secretagogue was recommended in the clinical protocols.

Thyroid C-cell effects are a class concern for GLP-1R agonists based on rodent carcinogenicity studies showing dose-dependent C-cell hyperplasia and medullary thyroid carcinoma at supraphysiological exposures. The clinical relevance of this finding in humans is uncertain; GLP-1R expression on human thyroid C-cells is substantially lower than in rodents. ^[7] Nevertheless, this is an important consideration when designing long-term animal studies with tirzepatide, as thyroid histopathology should be included in any chronic rodent study endpoint panel.

Safety Considerations Specific to Research Use

When handling reconstituted tirzepatide solutions in a research setting, standard peptide laboratory precautions apply: gloves, eye protection, and containment of spills. The compound does not appear in databases of occupational sensitizers or hazardous research chemicals, and at the concentrations used in typical laboratory protocols, systemic toxicity from accidental skin exposure is unlikely. Nevertheless, any inadvertent injection or mucosal contact should be treated per institutional first-aid and incident reporting protocols.

Waste disposal of tirzepatide solutions should follow institutional policies for research biochemicals. The compound is expected to degrade rapidly under standard wastewater treatment conditions due to protease activity, but consult your institution's environmental health and safety office for local requirements.

How It Compares

Tirzepatide vs. Semaglutide: The Critical Comparison

The most practically important comparison for metabolic researchers is tirzepatide versus semaglutide, as these two compounds represent the current frontline of approved GLP-based pharmacology and are the most commonly used reference compounds in the incretin research space. Both molecules use fatty acid acylation to extend half-life, both produce dose-dependent reductions in food intake and body weight, and both are available in research-grade formats from multiple suppliers.

The key mechanistic difference is GIPR activity. Semaglutide is a highly selective GLP-1R agonist with negligible GIPR affinity. Tirzepatide activates both receptors. Researchers who want to isolate GLP-1R biology should use semaglutide as the comparator; researchers who want to study the incremental contribution of GIPR agonism to metabolic outcomes should use tirzepatide versus semaglutide as a paradigm. The SURPASS-2 direct comparison trial, discussed above, provides the clinical benchmark for this comparison. ^[1]

From a practical standpoint in laboratory settings, semaglutide's slightly longer half-life (approximately 7 days versus 5 days for tirzepatide) and its C18 acylation (which is well-characterized in the literature) may offer some practical reconstitution stability advantages in certain assay formats. Tirzepatide's C20 diacid acylation is more novel and slightly less characterized in terms of laboratory handling behavior. Both should be treated with equivalent care regarding adsorption to surfaces at low concentrations.

Tirzepatide vs. Retatrutide: Triple vs. Dual Agonism

Retatrutide (LY3437943) is Eli Lilly's follow-on compound to tirzepatide, adding glucagon receptor (GcgR) agonism to the dual GLP-1R/GIPR profile. Phase 2 data published in 2023 showed mean weight reductions of approximately 24% over 48 weeks at the highest dose, modestly exceeding tirzepatide's SURMOUNT-1 results. ^[16] For researchers interested in the incremental contribution of glucagon receptor agonism to metabolic outcomes, using tirzepatide and retatrutide as a paired comparison (with appropriate single- and dual-receptor controls) is a productive study design.

The addition of glucagon receptor agonism in retatrutide theoretically increases energy expenditure through direct hepatic glucose production signaling and brown adipose tissue activation, effects that are distinct from the appetite-suppression pathways activated by GLP-1R and GIPR. Researchers should be aware that glucagon receptor activation can increase fasting glucose in the absence of counterbalancing insulinotropic effects, which may complicate interpretation in certain metabolic phenotyping models.

Where to Buy

Apollo Peptide Sciences lists this product at /product/glp-2-trz-500mcg-25-tablets, where the current price of $75.00 per 25-tablet unit is reflected. The product page includes the CoA request pathway and current stock status. We recommend reviewing the full Apollo Peptide Sciences supplier profile before placing an order, as this includes an assessment of their analytical documentation practices, batch-to-batch consistency records, and customer verification requirements.

For researchers comparing pricing across suppliers, our peptide supplier comparison guide covers six catalog vendors who stock tirzepatide or dual GIP/GLP-1 agonist research peptides, with an assessment of CoA quality, shipping practices, and documented purity consistency based on independent third-party testing.

FAQ